In this op-ed, former deputy U.S. trade representative Jeffrey Gerrish argues the Trump administration was right to launch a Section 301 investigation into Germany’s drug pricing, and says it should not stop there. Nearly every major trading partner, he writes, uses price controls that shift the cost of drug research onto American patients.
Jeffrey Gerrish
Ambassador Jeffrey Gerrish served as deputy U.S. trade representative for Asia, Europe, the Middle East and Industrial Competitiveness from 2018 to 2020.